. Inca, Estimation nationale de l'incidence et de la mortalité par cancer en France entre Partie 1 -Tumeurs solides http://lesdonnees.e-cancer.fr/les-fiches-de-synthese/1-types-cancer/14- melanome-cutane/44-epidemiologie-melanome-cutane-france- metropolitaine-incidence-mortalite, 1980.

M. J. Robinson and M. H. Cobb, Mitogen-activated protein kinase pathways, Current Opinion in Cell Biology, vol.9, issue.2, pp.180-186, 1997.
DOI : 10.1016/S0955-0674(97)80061-0

N. Cho, M. Choi, B. Kim, Y. Cho, K. Moon et al., BRAF andKRAS mutations in prostatic adenocarcinoma, International Journal of Cancer, vol.129, issue.8, pp.1858-1862, 2006.
DOI : 10.1002/ijc.22071

H. Davies, G. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-54, 2002.
DOI : 10.1006/geno.2000.6354

V. Goel, A. Lazar, C. Warneke, M. Redston, and F. Haluska, Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma, Journal of Investigative Dermatology, vol.126, issue.1, pp.154-60, 2006.
DOI : 10.1038/sj.jid.5700026

J. Han, G. Colditz, and D. Hunter, Risk factors for skin cancers: a nested case-control study within the Nurses' Health Study, International Journal of Epidemiology, vol.35, issue.6, pp.1514-1521, 2006.
DOI : 10.1093/ije/dyl197

A. Platz, S. Egyhazi, U. Ringborg, and J. Hansson, mutation frequencies in relation to histogenetic subclass and body site, Molecular Oncology, vol.19, issue.4, pp.395-405, 2008.
DOI : 10.1016/j.molonc.2007.12.003

N. Thomas, BRAF somatic mutations in malignant melanoma and melanocytic naevi, Melanoma Research, vol.16, issue.2, pp.97-103, 2006.
DOI : 10.1097/01.cmr.0000215035.38436.87

G. Long, A. Menzies, A. Nagrial, L. Haydu, A. Hamilton et al., Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma., Journal of Clinical Oncology, vol.28, issue.15_suppl, p.15, 2010.
DOI : 10.1200/jco.2010.28.15_suppl.8548

C. M. Lovly, . Dahlman, Z. Fohn, D. Su, D. J. Dias-santagata et al., Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials, PLoS ONE, vol.30, issue.4, 2012.
DOI : 10.1371/journal.pone.0035309.s015

P. Wan, M. Garnett, S. Roe, S. Lee, D. Niculescu-duvaz et al., Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF, Cell, vol.116, issue.6, pp.855-867, 2004.
DOI : 10.1016/S0092-8674(04)00215-6

P. Pollock, U. Harper, K. Hansen, L. Yudt, M. Stark et al., High frequency of BRAF mutations in nevi, Nature Genetics, vol.33, issue.1, p.19, 2003.
DOI : 10.1038/nm0798-844

C. Bock, G. Berchem, Y. Bruch, J. Genoux-hames, S. Meyer et al., Vemurafenib (zelboraf)

P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto et al., Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011.
DOI : 10.1056/NEJMoa1103782

H. Zelboraf, Commission de la transparence Avis 3 octobre 2012 http, zelboraf [16] HAS. Zelboraf, p.61477322

. Inca, Missions et domaines d'intervention. http://www.ecancer.fr/linstitut-national-du-cancer/presentation/missions-et-domaines- dintervention

P. Chapman, A. Hauschild, and V. Sondak, Frontline Approach to Metastatic BRAF-Mutant Melanoma Diagnosis, Molecular Evaluation, and Treatment Choice, American Society of Clinical Oncology Educational Book, vol.34, pp.412-433
DOI : 10.14694/EdBook_AM.2014.34.e412

E. Colomba, Z. Hélias-rodzewicz, V. Deimling, A. Marin, C. Terrones et al., Detection of BRAF p.V600E Mutations in Melanomas, The Journal of Molecular Diagnostics, vol.15, issue.1, pp.94-100, 2013.
DOI : 10.1016/j.jmoldx.2012.09.001

. Ronaghi, Pyrosequencing Sheds Light on DNA Sequencing, Genome Research, vol.11, issue.1, pp.3-11, 2001.
DOI : 10.1101/gr.11.1.3

C. Marin, A. Beauchet, D. Capper, U. Zimmermann, C. Julié et al., p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility, Archives of Pathology & Laboratory Medicine, vol.138, issue.1, pp.71-76, 2014.
DOI : 10.5858/arpa.2013-0031-OA

URL : https://hal.archives-ouvertes.fr/jpa-00235738

M. Pearlstein, D. Zedek, D. Ollila, A. Treece, M. Gulley et al., V600E mutation in melanoma, Journal of Cutaneous Pathology, vol.9, issue.9, pp.724-756, 2014.
DOI : 10.1111/cup.12364

H. Populo, P. Soares, A. Rocha, P. Silva, and J. Lopes, Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma, Melanoma Research, vol.20, issue.2, pp.107-117, 2010.
DOI : 10.1097/CMR.0b013e32832ccd09

M. Ilhe, J. Fassunke, K. König, I. Grünewald, M. Schlaak et al., Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations, BMC Cancer, vol.14, p.13, 2014.

L. Heinzerling, S. Kühnapfel, D. Meckbach, M. Baiter, E. Kaempgen et al., Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice, British Journal of Cancer, vol.108, issue.10, pp.2164-2171, 2013.
DOI : 10.1371/journal.pone.0029336

J. S. Wilmott, A. M. Menzies, L. E. Haydu, D. Capper, M. Preusser et al., BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma, British Journal of Cancer, vol.24, issue.4, pp.924-931, 2013.
DOI : 10.1371/journal.pone.0029336

. Inca, Missions et localisation des plateformes. http://www.ecancer.fr/soins/lacces-aux-therapies-ciblees/les-plateformes-de- genetique-moleculaire-des-cancers/missions-et-localisation-des- plateformes